Statement of Need

Myelofibrosis (MF) is a rare myeloproliferative neoplasm that has a poor prognosis, mostly due to leukemic transformation. Several novel approved therapies have shown efficacy in controlling symptoms of MF, improving patient quality of life, and extending overall survival. For patients to achieve therapeutic goals, clinicians must optimize treatment selection considerate of patient risk, monitor when to switch therapies, and mitigate the impact of disease symptoms and adverse events on patient quality of life. Given the rarity of MF and the rapid advances in risk assessment and therapy selection, clinicians require education on available data, coring systems, and evidence-based recommendations.

Target Audience

This activity is intended for hematologists/oncologists and other members of the multidisciplinary clinical management team practicing in both community and academic hospital settings and private practice.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the role of risk stratification for guiding treatment selection in myelofibrosis (MF)
  • Implement appropriate and timely risk-adapted treatment strategies following a diagnosis of MF
  • Discuss guideline-recommended monitoring response strategies to determine treatment success or failure in patients with MF

Method of Participation

To receive credit, participants are required to complete a self-assessment, an action plan, and view the online interventions. After a minimum of 30 days, participants are required to assess their progress relative to their action plan and complete a reflection survey detailing their involvement in the quality improvement initiative. A certificate will be available upon completion. There is no fee to participate in the activity or for the generation of the certificate.

For questions, contact Laurie Novoryta at Lnovoryta@ACHLcme.org

Accreditation and Credit Designation Statement


The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 CreditsTM through their reciprocity agreements.

MOC Part IV

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

By providing your ABIM Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system. ABIM credit will be submitted to PARS within 30 days of completion.

MIPS Improvement Activity

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

Disclosures

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

Brady Stein, MD, MHS(faculty) has no financial relationships to disclose

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Staff and Reviewer Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Acknowledgement

Provided by the Academy for Continued Healthcare Learning (ACHL).

This activity is supported by an educational grant from CTI BioPharma Corp.